These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32482751)

  • 1. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
    Sallman DA
    Haematologica; 2020 Jun; 105(6):1470-1472. PubMed ID: 32482751
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
    Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
    [No Abstract]   [Full Text] [Related]  

  • 4. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Maslah N; Diawara Y; Sebert M; Giraudier S; Fenaux P; Cassinat B
    Br J Haematol; 2021 Aug; 194(4):e77-e79. PubMed ID: 34145569
    [No Abstract]   [Full Text] [Related]  

  • 6. Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
    Maslah N; Rety S; Bonnamy M; Aguinaga L; Huynh T; Parietti V; Giraudier S; Fenaux P; Cassinat B
    Leukemia; 2024 Jul; 38(7):1630-1633. PubMed ID: 38777834
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
    Zeidan AM; Bewersdorf JP; Hasle V; Shallis RM; Thompson E; de Menezes DL; Rose S; Boss I; Halene S; Haferlach T; Fox B
    Leukemia; 2023 Jan; 37(1):240-243. PubMed ID: 36437356
    [No Abstract]   [Full Text] [Related]  

  • 8. Eprenetapopt (APR-246) and Azacitidine in
    Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
    J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Problem of TP53-Mutant MDS/AML.
    Sallman DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S65-S66. PubMed ID: 32862873
    [No Abstract]   [Full Text] [Related]  

  • 10. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for
    Mishra A; Tamari R; DeZern AE; Byrne MT; Gooptu M; Chen YB; Deeg HJ; Sallman D; Gallacher P; Wennborg A; Hickman DK; Attar EC; Fernandez HF
    J Clin Oncol; 2022 Dec; 40(34):3985-3993. PubMed ID: 35816664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azacitidine effectively reduces
    Takei T; Yokoyama K; Shimizu E; Konuma T; Takahashi S; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Leuk Lymphoma; 2018 Nov; 59(11):2755-2756. PubMed ID: 29648492
    [No Abstract]   [Full Text] [Related]  

  • 13. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Pereira MP; Herrity E; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
    Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
    Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
    Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
    Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
    [No Abstract]   [Full Text] [Related]  

  • 17. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 19. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
    N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
    Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.